Galapagos NV ADR (GLPG)

$31.96 -0.07 (-0.22%)
Market Cap 2.11B
Revenue (ttm) 298.28M
Net Income (ttm) 80.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 26.87%
Debt to Equity Ratio 0.00
Volume 134,300
Avg Vol 218,308
Day's Range N/A - N/A
Shares Out 65.90M
Stochastic %K 23%
Beta 0.28
Analysts Hold
Price Target $31.10

Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic...

Industry: Biotechnology
Sector: Healthcare
Phone: 32 1 534 29 00
Fax: 32 1 534 29 01
Address:
Generaal De Wittelaan L11 A3, Mechelen, Belgium
JarvisFlow
JarvisFlow Oct. 22 at 2:17 PM
RBC Capital updates rating for Galapagos ( $GLPG ) to Sector Perform, target set at 27 → 28.
0 · Reply
Readcarefully
Readcarefully Oct. 22 at 6:44 AM
$GLPG I always thought Galapagos was too small to compete in oncology. They should never have sold Jyseleca. What do they have left? 1. a completely failed management team 2. a bit of cash to buy a phase 1 or phase 2a product 3. non-motivated personnel after they have seen so many people being fired the last 2 years 4. a bad reputation among investors and in the pharmaceutical industry because of failure after failure
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:43 PM
Leerink Partners has adjusted their stance on Galapagos ( $GLPG ), setting the rating to Outperform with a target price of 29 → 40.
0 · Reply
GetVector
GetVector Oct. 21 at 12:54 PM
Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $EOSE, $GLPG, $VMI.
0 · Reply
MrMagician
MrMagician Oct. 21 at 11:53 AM
$SLS so one less potential competitor in our space as $GLPG folds, leaving us even more valuable as one fewer potential alternative treatment option is taken off the board! https://www.yourerie.com/business/press-releases/globenewswire/1001134116/galapagos-announces-intention-to-wind-down-cell-therapy-business-as-part-of-the-companys-ongoing-transformation/
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 11:42 AM
$GLPG
1 · Reply
notreload_ai
notreload_ai Oct. 21 at 10:39 AM
$GLPG winds down cell therapy business affecting 365 jobs across 5 countries after unsuccessful sale attempts. Stock drops 15% on announcement. https://notreload.xyz/galapagos-shuts-down-cell-therapy-division/
0 · Reply
dgbio
dgbio Oct. 21 at 8:25 AM
$GLPG Just wind out completely and give us cash.
0 · Reply
US_Bull
US_Bull Oct. 12 at 1:50 PM
$GLPG Exceptionally quiet board for a company whose cell-therapy arm may likely get BO soon. PR from Oct. 1.
1 · Reply
twincam
twincam Oct. 6 at 5:15 PM
$GLPG options are trading at elevated premiums, reflecting anticipated biotech event risk. Wide spreads and lower liquidity also contribute to richer pricing. The market’s pricing in movement, not complacency.
0 · Reply
Latest News on GLPG
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Oct 23, 2025, 4:01 PM EDT - 2 days ago

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Biotech firm Galapagos to wind down cell therapy business

Oct 21, 2025, 3:34 AM EDT - 4 days ago

Biotech firm Galapagos to wind down cell therapy business

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Oct 21, 2025, 1:30 AM EDT - 4 days ago

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Oct 16, 2025, 4:01 PM EDT - 9 days ago

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Biotechnology firm Galapagos receives offers for cell-therapy business

Oct 1, 2025, 4:12 PM EDT - 24 days ago

Biotechnology firm Galapagos receives offers for cell-therapy business

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Oct 1, 2025, 4:01 PM EDT - 24 days ago

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

Galapagos Creates New Subscription Right Plan

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Galapagos Creates New Subscription Right Plan

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Aug 6, 2025, 1:30 AM EDT - 2 months ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Jul 23, 2025, 4:03 PM EDT - 3 months ago

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Jul 23, 2025, 4:02 PM EDT - 3 months ago

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Jul 23, 2025, 4:01 PM EDT - 3 months ago

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Galapagos Appoints Aaron Cox as Chief Financial Officer

Jun 23, 2025, 1:30 AM EDT - 4 months ago

Galapagos Appoints Aaron Cox as Chief Financial Officer

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Jun 18, 2025, 4:01 PM EDT - 4 months ago

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Jun 12, 2025, 4:01 PM EDT - 4 months ago

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

May 13, 2025, 1:36 AM EDT - 5 months ago

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101

Apr 25, 2025, 6:16 PM EDT - 6 months ago

Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101

Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 11:34 AM EDT - 6 months ago

Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Apr 23, 2025, 4:01 PM EDT - 6 months ago

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Apr 15, 2025, 1:30 AM EDT - 6 months ago

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Mar 27, 2025, 4:01 PM EDT - 7 months ago

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

Galapagos to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:01 PM EST - 8 months ago

Galapagos to Present at Upcoming Investor Conferences

Disount To Net Cash For A Promising CAR-T Company

Feb 20, 2025, 7:13 AM EST - 8 months ago

Disount To Net Cash For A Promising CAR-T Company

Galapagos receives transparency notification and 13D filing from Tang Capital

Feb 17, 2025, 4:01 PM EST - 8 months ago

Galapagos receives transparency notification and 13D filing from Tang Capital

Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 1:26 PM EST - 9 months ago

Galapagos NV (GLPG) Q4 2024 Earnings Call Transcript

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Feb 12, 2025, 4:01 PM EST - 9 months ago

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos To Spin Off Innovative Medicines Business

Jan 21, 2025, 12:08 PM EST - 9 months ago

Galapagos To Spin Off Innovative Medicines Business

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Jan 8, 2025, 1:30 AM EST - 10 months ago

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 10 months ago

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Dec 7, 2024, 12:30 PM EST - 11 months ago

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Nov 5, 2024, 4:01 PM EST - 1 year ago

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 3:50 PM EDT - 1 year ago

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Oct 7, 2024, 1:00 AM EDT - 1 year ago

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Oct 1, 2024, 6:00 AM EDT - 1 year ago

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Galapagos receives transparency notification from EcoR1 Capital

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from FMR LLC

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Galapagos receives transparency notification from FMR LLC

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Aug 23, 2024, 3:49 PM EDT - 1 year ago

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Aug 23, 2024, 1:00 AM EDT - 1 year ago

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 1:25 PM EDT - 1 year ago

Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Aug 1, 2024, 4:01 PM EDT - 1 year ago

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos reports half-year 2024 financial results and provides second quarter business update

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Galapagos reports half-year 2024 financial results and provides second quarter business update

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

ADAP

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

ADAP

Galapagos creates new subscription right plans

May 16, 2024, 4:01 PM EDT - 1 year ago

Galapagos creates new subscription right plans

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

May 15, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript

May 4, 2024, 11:51 AM EDT - 1 year ago

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript

Galapagos reports first quarter 2024 financial results

May 2, 2024, 4:01 PM EDT - 1 year ago

Galapagos reports first quarter 2024 financial results

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Apr 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Apr 4, 2024, 4:01 PM EDT - 1 year ago

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

JarvisFlow
JarvisFlow Oct. 22 at 2:17 PM
RBC Capital updates rating for Galapagos ( $GLPG ) to Sector Perform, target set at 27 → 28.
0 · Reply
Readcarefully
Readcarefully Oct. 22 at 6:44 AM
$GLPG I always thought Galapagos was too small to compete in oncology. They should never have sold Jyseleca. What do they have left? 1. a completely failed management team 2. a bit of cash to buy a phase 1 or phase 2a product 3. non-motivated personnel after they have seen so many people being fired the last 2 years 4. a bad reputation among investors and in the pharmaceutical industry because of failure after failure
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:43 PM
Leerink Partners has adjusted their stance on Galapagos ( $GLPG ), setting the rating to Outperform with a target price of 29 → 40.
0 · Reply
GetVector
GetVector Oct. 21 at 12:54 PM
Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $EOSE, $GLPG, $VMI.
0 · Reply
MrMagician
MrMagician Oct. 21 at 11:53 AM
$SLS so one less potential competitor in our space as $GLPG folds, leaving us even more valuable as one fewer potential alternative treatment option is taken off the board! https://www.yourerie.com/business/press-releases/globenewswire/1001134116/galapagos-announces-intention-to-wind-down-cell-therapy-business-as-part-of-the-companys-ongoing-transformation/
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 11:42 AM
$GLPG
1 · Reply
notreload_ai
notreload_ai Oct. 21 at 10:39 AM
$GLPG winds down cell therapy business affecting 365 jobs across 5 countries after unsuccessful sale attempts. Stock drops 15% on announcement. https://notreload.xyz/galapagos-shuts-down-cell-therapy-division/
0 · Reply
dgbio
dgbio Oct. 21 at 8:25 AM
$GLPG Just wind out completely and give us cash.
0 · Reply
US_Bull
US_Bull Oct. 12 at 1:50 PM
$GLPG Exceptionally quiet board for a company whose cell-therapy arm may likely get BO soon. PR from Oct. 1.
1 · Reply
twincam
twincam Oct. 6 at 5:15 PM
$GLPG options are trading at elevated premiums, reflecting anticipated biotech event risk. Wide spreads and lower liquidity also contribute to richer pricing. The market’s pricing in movement, not complacency.
0 · Reply
stockMDG
stockMDG Oct. 5 at 6:18 PM
$GLPG confused. If glpg sells cell therapy what doesnit have left. It sold jysselica now what.
1 · Reply
michele3
michele3 Oct. 5 at 4:34 PM
$ADAP $GLPG I’m trying to understand… glpg is going to sell its cell therapy by November 5… how is that going to impact Adap and in what way please
4 · Reply
US_Bull
US_Bull Oct. 5 at 2:45 PM
$GLPG $ADAP See below.
1 · Reply
twincam
twincam Oct. 2 at 11:51 PM
$GLPG 🚨 Galapagos (GLPG) confirmed it has received non-binding offers for its cell therapy unit. Binding bids due in weeks, with a decision expected by Nov 5. Analysts still sit around $26–32 PT, but a $1.5–2B sale could imply upside toward $55–70
0 · Reply
EarlyEntryNoob
EarlyEntryNoob Oct. 2 at 5:25 PM
$GLPG 0.1270 is definitely the number they have chosen. Chart shows it, LvL2 shows it. So the question is how many do they want before letting it go?
0 · Reply
US_Bull
US_Bull Oct. 2 at 2:08 PM
$ADAP $GLPG EcoR1 owns a big chunk of GLPG and ADAP and founder is a Director on the Board of GLPLG.
0 · Reply
US_Bull
US_Bull Oct. 2 at 2:07 PM
$GLPG $ADAP I wonder if today's news will have an impact on us. So we sold the rights of our cell-based products to USWorldmeds and they partner with Galapagos to further develop the non-commercialized product as of yet.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 1 at 8:49 PM
$GLPG
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 8:54 AM
$GLPG Brilliant piece that captures GLPG's situation perfectly. So if you want to update your understanding of GLPG or get to know GLPG better, this is essential reading. https://beyondspx.com/quote/GLPG/analysis/galapagos-charts-a-new-course-cell-therapy-innovation-fuels-oncology-ambition-nasdaq-glpg
0 · Reply
AZ89
AZ89 Sep. 21 at 1:14 AM
$ADAP @US_Bull @LezGoh and other longs so how does US WorldMeds play into all of this? Because ADAP sold some assets to them does this affect their deal with $GLPG? Thanks
1 · Reply
Market_Luther_Kang
Market_Luther_Kang Sep. 6 at 3:53 PM
$GLPG did more research and it seems they're looking to sell their cell therapy pipeline which is a good reason why it's stuck in limbo. I think they'll find a buyer within a year. Pretty efficacious lead asset with RMAT designation - its essentially de-risked. I hope that cash-flush Pfizer picks it up because they desperately need something + they've the size and capital to make this work. Good time to accumulate shares of Galapagos. Fingers crossed they make a great acquisition after selling their pipeline.
0 · Reply
Market_Luther_Kang
Market_Luther_Kang Sep. 3 at 3:01 AM
$GLPG checked out the efficacy on their lead asset from the phase 2 readout and I'm scratching my head on why this is so undervalued. I know they messed up terribly in the past and had to revamp the entire pipeline but it's looking solid here. Lot of potential so is there something I'm missing? Either way, it's worth the gamble so I'll be adding here.
0 · Reply